FDA widens use of Pfizer prostate cancer combo

Unbranded prostate cancer drug blister packs in a clinic, highlighting expanded FDA approval for treatment combo

Key Points

01FDA expands approval for Talzenna plus Xtandi in metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with HRR mutations
02Phase 3 TALAPRO-3 trial in 599 patients showed a 52% reduction in risk of radiographic progression or death versus placebo plus Xtandi
03An estimated 77% of patients on the Talzenna and Xtandi regimen remained progression-free at three years
04The expanded indication covers BRCA and non-BRCA HRR mutations and was granted Priority Review, with EMA review also underway

FDA expands Talzenna plus Xtandi use in prostate cancer

The U.S. Food and Drug Administration has expanded the approval of Pfizer (PFE)'s Talzenna (talazoparib) in combination with Xtandi (enzalutamide) for the treatment of men with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with homologous recombination repair (HRR) gene mutations. This decision allows the combination therapy to be used in an earlier metastatic treatment setting than previously authorized, broadening access for eligible patients.

The expanded indication includes both BRCA and non-BRCA HRR mutations. Eligibility for treatment with the Talzenna and Xtandi regimen is determined using an FDA-authorized test, aligning the approval with biomarker-driven patient selection.

Clinical evidence from the TALAPRO-3 trial

The FDA's decision is supported by data from the Phase 3 TALAPRO-3 study, which enrolled 599 men with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer at sites across the U.S., Canada, Europe, South America, and Asia-Pacific. In this trial, treatment with Talzenna plus Xtandi reduced the risk of radiographic progression or death by 52% compared with placebo plus Xtandi, corresponding to a hazard ratio of 0.48.

In addition to the reduction in risk of progression or death, an estimated 77% of patients receiving the combination therapy remained progression-free at three years. These outcomes formed the clinical basis for the expanded approval in this earlier disease setting.

Safety profile and adverse events

The application for the expanded indication was reviewed under the FDA's Priority Review program. The safety profile of the Talzenna and Xtandi combination was consistent with the known profiles of each agent. The most common treatment-emergent adverse events in the combination group were anemia, fatigue, decreased neutrophil count, and asthenia.

Anemia was the most frequent grade 3 or higher adverse event, occurring in 51% of patients in the Talzenna plus Xtandi group compared with 3% in the control group. As a result of anemia, 5% of patients discontinued Talzenna. Despite these events, the overall safety findings aligned with expectations for the individual drugs in the regimen.

Disease setting and mechanism of action

Approximately 25% of men with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer are estimated to harbor HRR gene mutations, making this biomarker-defined group a significant subset of the overall patient population. The expanded indication targets this HRR-mutated group, including castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, and nonmetastatic castration-sensitive prostate cancer with high-risk biochemical recurrence.

Talzenna is an oral poly ADP-ribose polymerase (PARP) inhibitor, while Xtandi is an androgen receptor pathway inhibitor. The combination is designed to address both DNA damage repair pathways and androgen receptor signaling, reflecting a dual-mechanism approach in this HRR-mutated metastatic prostate cancer population.

Global regulatory outlook

Beyond the United States, an application for Talzenna in combination with Xtandi for a similar metastatic HRR-mutated prostate cancer population is under review by the European Medicines Agency. Additional regulatory submissions are planned or underway in other regions, aiming to extend access to the combination therapy in global markets.

Key Takeaways

01The expanded FDA approval moves Talzenna plus Xtandi into an earlier metastatic prostate cancer setting for patients with HRR mutations, broadening treatment options.
02Robust Phase 3 TALAPRO-3 data, including a 52% reduction in radiographic progression or death and durable three-year progression-free outcomes, underpinned the decision.
03While efficacy gains are notable, high rates of anemia and other hematologic adverse events highlight the importance of careful monitoring and risk management with the regimen.

References